Kymera Therapeutics’ (KYMR) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Kymera Therapeutics (NASDAQ:KYMR – Free Report) in a research report released on Friday, Benzinga reports. They currently have a $46.00 price target on the stock. A number of other research firms have also recently issued reports on KYMR. Oppenheimer dropped their price objective on Kymera Therapeutics […]
More Stories
Fox Co. (NASDAQ:FOX) Short Interest Up 39.1% in September
Fox Co. (NASDAQ:FOX – Get Free Report) was the target of a large increase in short interest in the month...
CVB Financial Corp. (NASDAQ:CVBF) Short Interest Update
CVB Financial Corp. (NASDAQ:CVBF – Get Free Report) saw a significant decline in short interest in September. As of September...
Sabine Royalty Trust (NYSE:SBR) Sees Large Drop in Short Interest
Sabine Royalty Trust (NYSE:SBR – Get Free Report) was the recipient of a large decrease in short interest during the...
bioMérieux S.A. (OTCMKTS:BMXMF) Short Interest Update
bioMérieux S.A. (OTCMKTS:BMXMF – Get Free Report) was the target of a significant drop in short interest during the month...
Short Interest in Camden National Co. (NASDAQ:CAC) Expands By 31.5%
Camden National Co. (NASDAQ:CAC – Get Free Report) was the target of a significant increase in short interest during the...
Global X NASDAQ 100 Risk Managed Income ETF (NASDAQ:QRMI) Short Interest Up 48.8% in September
Global X NASDAQ 100 Risk Managed Income ETF (NASDAQ:QRMI – Get Free Report) saw a large growth in short interest...